Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$5.58 USD
0.00 (0.00%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $5.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Oncobiologics, Inc falls in the month of September.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -58.98 | -66.05 | -53.16 | -35.24 | -34.52 |
Depreciation/Amortization & Depletion | 0.04 | 0.20 | 0.26 | 0.55 | 3.36 |
Net Change from Assets/Liabilities | 4.75 | -1.68 | -7.08 | -1.27 | -13.19 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.21 | 10.86 | 5.73 | 4.17 | 12.07 |
Net Cash From Operating Activities | -42.97 | -56.67 | -54.25 | -31.79 | -32.29 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | -0.44 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | -0.90 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -0.90 | -0.44 |
Uses of Funds
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 30.02 | 62.51 | 49.90 | 36.57 | 45.97 |
Issuance (Repayment) of Debt | 19.77 | -2.32 | 6.31 | 0.64 | -6.94 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.82 | -0.60 | -0.01 | 0.00 | 0.00 |
Net Cash from Financing Activities | 48.97 | 59.59 | 56.19 | 37.21 | 39.03 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 6.00 | 2.92 | 1.94 | 4.52 | 6.30 |
Cash at Beginning of Period | 17.40 | 14.48 | 12.54 | 8.02 | 1.72 |
Cash at End of Period | 23.39 | 17.40 | 14.48 | 12.54 | 8.02 |
Diluted Net EPS | -4.80 | -6.20 | -7.00 | -13.40 | -39.60 |
Fiscal Year End for Oncobiologics, Inc falls in the month of September.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -81.06 | -125.47 | -11.18 | -58.98 | -45.99 |
Depreciation/Amortization & Depletion | 0.09 | 0.06 | 0.03 | 0.04 | 0.03 |
Net Change from Assets/Liabilities | -7.24 | -5.46 | -4.20 | 4.75 | 6.74 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 36.40 | 98.57 | 2.32 | 11.21 | 8.99 |
Net Cash From Operating Activities | -51.81 | -32.30 | -13.03 | -42.97 | -30.23 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 60.45 | 56.14 | 0.00 | 30.02 | 27.60 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 19.77 | 19.77 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.82 | -0.82 |
Net Cash from Financing Activities | 60.44 | 56.14 | 0.00 | 48.97 | 46.54 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 8.63 | 23.84 | -13.04 | 6.00 | 16.31 |
Cash at Beginning of Period | 23.39 | 23.39 | 23.39 | 17.40 | 17.40 |
Cash at End of Period | 32.02 | 47.23 | 10.36 | 23.39 | 33.71 |
Diluted Net EPS | -0.89 | -8.01 | -0.80 | -1.00 | -1.60 |